Rosner Mitchell H, Bolton W Kline
Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
Kidney Int. 2008 Sep;74(6):695-7. doi: 10.1038/ki.2008.263.
Recent trials have demonstrated a trend for increased mortality when patients with end-stage renal disease (ESRD) or chronic kidney disease (CKD) are treated with erythropoietin-stimulating agents (ESAs) to hemoglobin levels higher than recommended (>13 g/dl). Recent studies suggest that higher doses of ESAs, in themselves, may be at least partly responsible for this mortality risk. This is important, as more than 90% of patients with ESRD and approximately 20% of patients with CKD receive ESAs. Two new studies address this.
近期试验表明，终末期肾病（ESRD）或慢性肾病（CKD）患者接受促红细胞生成素刺激剂（ESAs）治疗使血红蛋白水平高于推荐值（>13 g/dl）时，死亡率有上升趋势。近期研究表明，ESAs剂量较高本身可能至少部分导致了这种死亡风险。这一点很重要，因为超过90%的ESRD患者和约20%的CKD患者接受ESAs治疗。两项新研究探讨了这一问题。
